Citations

Showing 10 of 108094 citations.

Comprehensive Diabetes Autoantibody Laboratory-Based Clinical Service Testing in 6044 Consecutive Patients: Analysis of Age and Sex Effects
Dahl, Amanda , Jenkins, Sarah M. , Pittock, Sean J. , Mills, John R. , Foster, Jesica, Pittock, Siobhán T. , Pittock, Siobhan , Pittock, S J , McKeon, Andrew

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 28, 2022 | Volume: 7 | Issue: 5 | Pages: 1037-1046

10.1093/jalm/jfac037 | PMID 35899533 Get It

Abstract Background In 2017, Mayo Clinic Laboratories commenced offering a comprehensive type 1 diabetes mellitus (T1DM) autoantibody (Ab) evaluation including 4 known Abs targeting glutamic acid decarboxylase (GAD65), protein tyrosine phosphatase-like islet antigen 2 (IA2), insulin (IAA), and zinc transporter 8 protein (ZnT8) antigens. Methods The objective of this study was to evaluate real-time data on the frequency and patterns of all 4 Abs stratified by age and sex from 6044 unique consecutive adult and pediatric patients undergoing evaluation for suspected diabetes. Results At least one Ab was found in 3370 (56%) of all samples: 67% of children (aged 0–17), 49% of young adults (aged 18–35), and 41% for both middle-aged (aged 36–55) and older (aged >55) adults (P ≤ 0.0001). GAD65-Abs were the most common in all age groups, followed by ZnT8-Ab in those <36 years, or IAA-Ab in those ≥36. Frequencies of IA2- and ZnT8-Abs drop significantly with increasing age. Clusters of 3 or 4 Abs were more frequently encountered in younger patients (41% of children vs 12% in middle- and 13% in older age groups, P ≤ 0.0001). Conclusions Children undergoing serological evaluation for T1DM were more commonly positive for autoantibodies than older age groups. The frequency of ZnT8- and IA2-Abs decreases, and IAA-Ab frequency increases with increasing age, and clusters of 2 to 4 autoantibodies are more common in children. In clinical practice, comprehensive testing for diabetes autoantibodies resulted in a switch in diagnosis to T1DM for patients previously classified as type 2 diabetes mellitus.
Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus
Doyle, Alfred D. , Masuda, Mia Y. , Pyon, Grace C., Luo, Huijun , Putikova, Arina, LeSuer, William E., Flashner, Samuel , Rank, Matthew A. , Kita, Hirohito , Wright, Benjamin L. , Kita, H , Wright, Benjamin L , Nakagawa, Hiroshi

Mayo Clinic

Allergy | July 28, 2022 | Volume: 78 | Issue: 1 | Pages: 192-201

10.1111/all.15457 | PMID 35899466 Get It

AbstractBackgroundEosinophilic esophagitis (EoE) is a chronic allergic disease associated with type 2 inflammation and epithelial barrier dysfunction. The etiology is unknown, however, genetic heritability studies suggest environmental factors play a key role in pathogenesis. Detergents, such as sodium dodecyl sulfate (SDS), are common ingredients in household products such as dish soap and toothpaste. We hypothesized detergent exposure decreases epithelial barrier function and induces esophageal inflammation.MethodsImmortalized esophageal epithelial cells (EPC2) were cultured in air‐liquid interface (ALI) and exposed to SDS. Barrier function/activity was assessed by transepithelial electrical resistance (TEER), FITC‐dextran flux, and RT‐PCR. Additionally, SDS‐treated mouse esophageal organoids were evaluated for morphology. To investigate the effects of SDS in vivo, mice were treated with 0.5% SDS in drinking water for 14 days. Esophagi were assessed by gross morphology, histopathology, protein expression, and bulk RNA sequencing.ResultsWhen EPC2 cells were exposed to SDS (5 μg/ml) for 96 h, TEER decreased (p = 0.03), and FITC‐dextran flux increased (p = 0.0002). mRNA expression of IL‐33 increased 4.5‐fold (p = 0.02) at 6 h and DSG1 decreased (p < 0.0001) by 72 h. Disrupted epithelial integrity was noted in SDS‐treated esophageal organoids. When mice were exposed to SDS, they showed increased esophageal width, chemokine, and metalloprotease levels. Mice treated with SDS also showed increased IL‐33 protein expression, basal zone hyperplasia, CD4+ cell infiltration, and esophageal eosinophilia. RNA sequencing revealed upregulation of immune response pathway genes.ConclusionExposure to SDS decreases esophageal barrier integrity, stimulates IL‐33 production, and promotes epithelial hyperplasia and tissue eosinophilia. Detergents may be a key environmental trigger in EoE pathogenesis.
Electronic health records and blockchain interoperability requirements: a scoping review
Schmeelk, Suzanna , Kanabar, Megha , Pathak, Jyotishman , Peterson, Kevin

Mayo Clinic

JAMIA Open | July 28, 2022 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooac068 | PMID 35911668 Get It

Abstract Objective The purpose of this study was to conduct a scoping review of publications that explored blockchain technology in the context of interoperability and challenges of electronic health record (EHR) implementations. We synthesize the literature regarding standards and security, specifically regulation, regulatory operability, and conformance to standards. We review open practitioner questions that were not addressed in the studies as directions for further research. Materials and Methods We conducted a literature search in the OVID databases (Medline and Embase) on terms blockchain, implementation, interoperability, EHRs, security, and standards. The search resulted in 152 nonduplicate, peer-reviewed manuscripts, of which 15 were relevant to our objective and included for synthesis. Results Based on the search results, we analyzed the adoption of blockchain technology in the healthcare systems and challenges to EHR implementation of blockchain. From the synthesized research, we categorized and reported compelling factors of blockchain for EHR integration using current knowledge on blockchain research standardization and architectural challenges. Discussion Our research showed promise in implementing blockchain technology associated with EHRs, especially with Health Information Exchanges. The studies relevant for both EHR (n = 5) and blockchain (n = 10) reported compelling factors and limitations of the architecture. Security (n = 4) and interoperability (n = 4) features were reported as compelling requirements with lingering challenges. Standardization literature (n = 3) reported implementation challenges. Conclusion This study shows promise in implementing blockchain technology within EHR systems. The adoption is increasing; however, multiple implementation challenges remain from architectural perspectives (eg, scalability and performance), to security challenges (eg, legal requirements), and standard perspectives including patient-matching problems.
Leadership Diversity and Development in the Nation’s Cancer Centers
Lerman, Caryn , Halbert, Chanita Hughes , Falcone, Mary , Gosky, David M., Jensen, Roy A. , Lee, Kelvin P., Mitchell, Edith P. , Odunsi, Kunle , Pegher, Jennifer W, Rodriguez, Elisa M. , Sánchez, Yolanda , Hughes-Halbert, Chanita , Mitchell, Edith , Shaw, Reuben , Weiner, George , Weiner, George J. , Willman, Cheryl L.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 28, 2022 | Volume: 114 | Issue: 9 | Pages: 1214-1221

10.1093/jnci/djac121 | PMID 35897143 Get It

Abstract The capacity and diversity of the oncology leadership workforce has not kept pace with the emerging needs of our increasingly complex cancer centers and the spectrum of challenges our institutions face in reducing the cancer burden in diverse catchment areas. Recognizing the importance of a diverse workforce to reduce cancer inequities, the Association of American Cancer Institutes conducted a survey of its 103 cancer centers to examine diversity in leadership roles from research program leaders to cancer center directors. A total of 82 (80%) centers responded, including 64 National Cancer Institute–designated and 18 emerging centers. Among these 82 respondents, non-Hispanic White individuals comprised 79% of center directors, 82% of deputy directors, 72% of associate directors, and 72% of program leaders. Women are underrepresented in all leadership roles (ranging from 16% for center directors to 45% for associate directors). Although the limited gender, ethnic, and racial diversity of center directors and perhaps deputy directors is less surprising, the demographics of current research program leaders and associate directors exposes a substantial lack of diversity in the traditional cancer center senior leadership pipeline. Sole reliance on the cohort of current center leaders and leadership pipeline is unlikely to produce the diversity in cancer center leadership needed to facilitate the ability of those centers to address the needs of the diverse populations they serve. Informed by these data, this commentary describes some best practices to build a pipeline of emerging leaders who are representative of the diverse populations served by these institutions and who are well positioned to succeed.
Making Decisions About Krabbe Disease Newborn Screening
Kurtzberg, Joanne, Matern, Dietrich , Orsini, Joseph J. , Gelb, Michael H. , Pike‐Langenfeld, Stacy, Brackbill, Lesa , Grantham, Anna, Steyermark, Anthony C., Kurtzberg, Joanne , Grantham, Anna

Mayo Clinic

Pediatrics | July 28, 2022 | Volume: 150 | Issue: 2 | Pages: No page available

10.1542/peds.2022-057888a | PMID 35896799 Get It

Tumour-induced osteomalacia: a rare cause of chronic pain and weakness
Nasr, John T , Tohme, Jack F., Dockery, Keith, Taskin, Metin, Sfeir, Jad , Collins, Michael Terrence , Drake, Matthew T. , Hartley, Iris Ruth

Mayo Clinic

Practical Neurology | July 28, 2022 | Volume: 22 | Issue: 6 | Pages: 528-531

10.1136/pn-2022-003394 | PMID 35896375 Get It

Tumor-induced osteomalacia is a rare and often misdiagnosed condition that presents with progressively worsening unexplained chronic pain and proximal muscle weakness. The osteomalacia leads to multiple stress fractures which do not heal properly, leading to progressive disability. It is caused by chronic hypophosphatemia due to inappropriate urinary phosphate wasting. This is due to a typically benign mesenchymal tumor that over-secretes a phospaturic hormone. Neurologists need to appreciate the relevance of chronic hypophosphatemia in people with chronic unexplained pain, as timely diagnosis and treatment of tumour-induced osteomalacia can be curative.
Fifty-point IBS-SSS responders but persistence of moderate severity IBS in over 40% of those on diet
Camilleri, Michael

Mayo Clinic

Gut | July 28, 2022 | Volume: 72 | Issue: 6 | Pages: 1226.2-1227

10.1136/gutjnl-2022-328211 | PMID 35882563 Get It

Revisiting Pituitary Apoplexy
Donegan, Diane , Erickson, Dana

Mayo Clinic

Journal of the Endocrine Society | July 28, 2022 | Volume: 6 | Issue: 9 | Pages: No page available

10.1210/jendso/bvac113 | PMID 35928242 Get It

Abstract Pituitary apoplexy (PA) is a rare clinical syndrome due to pituitary hemorrhage or infarction. It is characterized by the sudden onset of one or more of the following: severe headache, visual disturbance, nausea/vomiting, and or altered mental status. Most commonly, PA occurs in an underlying pituitary adenoma. The pathophysiology is not fully understood, but it is thought to involve elements of increased metabolic demand and/or compromise to the vasculature of the pituitary or pituitary tumor. Several risk factors have been described. Stabilization of the patient on presentation, replacement of hormonal deficiencies, and reversal of electrolyte abnormalities are the recommended initial steps in the management of patients with PA. Surgical decompression of the mass effect had been the recommended treatment for patients with PA; however, retrospective studies of patients with PA have demonstrated similar outcomes when a conservative approach is applied. This suggests that in highly selected clinical scenarios (mild visual deficit and improving symptoms), conservative management is possible. Further studies, however, are necessary to better stratify patients but are limited by the rarity of the condition and the acuity.
Developing pharmacy services in a home hospital program: The Mayo Clinic experience
Peinovich, Margaret, Darracott, Robert M., Dow, Jordan, Darracott, Robert, Peinovich, Margaret

Mayo Clinic

American Journal of Health-System Pharmacy | July 28, 2022 | Volume: 79 | Issue: 21 | Pages: 1925-1928

10.1093/ajhp/zxac200 | PMID 35896358 Get It

Abstract Purpose Home hospital programs are rapidly becoming a more common patient care model in the market. The impact on hospital pharmacy practices is not well defined. This article describes the development of pharmacy services in a home hospital program in an attempt to help other organizations create their own home hospital pharmacy programs. Summary Caring for acutely ill patients in their home was a novel idea when Mayo Clinic began considering this in January 2020. Since then, the coronavirus disease 2019 (COVID-19) pandemic has rapidly escalated interest in and pursuit of these programs. One question we asked ourselves, and many colleagues are asking us today, is “How does pharmacy fit in?” Through 2 years of active engagement, innovation, and persistence, our team has developed a robust pharmacy presence in the home hospital care team and a well-articulated approach to medication management for our patients. We have tightly aligned and blended our clinical efforts to mirror our typical inpatient and ambulatory care clinical activities. We have also developed and modified our dispensing functions to serve the unique needs of the care model. Conclusion Home hospital medication management is both complex and ripe with opportunities for pharmacy engagement.
The incidence of brainstem toxicity following high-dose conformal proton therapy for adult skull-base malignancies
Holtzman, Adam L. , Rutenberg, Michael S. , Leo, Alexandra N. De , Rao, Dinesh , Patel, Jeet , Morris, Christopher G. , Indelicato, Daniel J. , Mendenhall, William M , Holtzman, Adam , Indelicato, Daniel J

Mayo Clinic

Acta Oncologica | July 27, 2022 | Volume: 61 | Issue: 8 | Pages: 1026-1031

10.1080/0284186x.2022.2101900 | PMID 35897132 Get It